CDADC1 and cancer: Thus, CDADC1 promotes gemcitabine resistance in human cancer cells, and its deletion enhances gemcitabine efficacy in vivo, primarily by increasing cytostatic and apoptotic effects, although we cannot formally rule out a contribution of the adaptive immunity.